Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lupus Erythematosus, Systemic | 77 | 2023 | 192 | 21.330 |
Why?
|
Quality of Life | 41 | 2023 | 660 | 7.820 |
Why?
|
Surveys and Questionnaires | 22 | 2023 | 1216 | 2.850 |
Why?
|
Severity of Illness Index | 28 | 2020 | 992 | 2.470 |
Why?
|
Health Status | 11 | 2018 | 228 | 2.430 |
Why?
|
Patient Reported Outcome Measures | 11 | 2021 | 508 | 2.300 |
Why?
|
Psychometrics | 16 | 2022 | 242 | 2.290 |
Why?
|
Rheumatology | 6 | 2019 | 85 | 1.910 |
Why?
|
Adult | 55 | 2022 | 8152 | 1.910 |
Why?
|
Body Image | 6 | 2017 | 27 | 1.890 |
Why?
|
Self Report | 8 | 2023 | 226 | 1.750 |
Why?
|
Female | 66 | 2022 | 15793 | 1.690 |
Why?
|
Middle Aged | 48 | 2021 | 9306 | 1.680 |
Why?
|
Humans | 86 | 2023 | 28462 | 1.590 |
Why?
|
Reproducibility of Results | 20 | 2022 | 726 | 1.460 |
Why?
|
Cross-Cultural Comparison | 9 | 2022 | 39 | 1.430 |
Why?
|
Patient Outcome Assessment | 3 | 2015 | 41 | 1.380 |
Why?
|
Hydroxychloroquine | 3 | 2021 | 10 | 1.320 |
Why?
|
Male | 49 | 2022 | 15367 | 1.300 |
Why?
|
Lupus Erythematosus, Discoid | 3 | 2021 | 9 | 1.240 |
Why?
|
Antirheumatic Agents | 3 | 2021 | 86 | 1.230 |
Why?
|
Rheumatologists | 2 | 2018 | 15 | 1.180 |
Why?
|
Pain | 7 | 2020 | 406 | 1.010 |
Why?
|
Cross-Sectional Studies | 14 | 2021 | 939 | 1.000 |
Why?
|
Fatigue | 4 | 2020 | 65 | 0.920 |
Why?
|
Lupus Erythematosus, Cutaneous | 2 | 2014 | 5 | 0.890 |
Why?
|
Health Status Indicators | 3 | 2014 | 75 | 0.870 |
Why?
|
Interferon-alpha | 7 | 2014 | 32 | 0.790 |
Why?
|
Pneumococcal Infections | 1 | 2021 | 7 | 0.770 |
Why?
|
Depression | 4 | 2020 | 454 | 0.760 |
Why?
|
Quality of Health Care | 3 | 2023 | 126 | 0.740 |
Why?
|
Antibodies, Antinuclear | 5 | 2018 | 13 | 0.720 |
Why?
|
Sickness Impact Profile | 4 | 2014 | 13 | 0.720 |
Why?
|
Pain Measurement | 5 | 2019 | 473 | 0.720 |
Why?
|
Lupus Nephritis | 2 | 2017 | 32 | 0.620 |
Why?
|
Outpatient Clinics, Hospital | 1 | 2018 | 15 | 0.620 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2018 | 25 | 0.610 |
Why?
|
Quality Indicators, Health Care | 1 | 2018 | 38 | 0.600 |
Why?
|
Academic Medical Centers | 1 | 2019 | 137 | 0.580 |
Why?
|
Cost of Illness | 2 | 2015 | 53 | 0.570 |
Why?
|
Young Adult | 12 | 2020 | 2100 | 0.570 |
Why?
|
Factor Analysis, Statistical | 7 | 2020 | 63 | 0.570 |
Why?
|
Sleep Wake Disorders | 1 | 2019 | 130 | 0.570 |
Why?
|
Unnecessary Procedures | 1 | 2017 | 30 | 0.550 |
Why?
|
Culture | 2 | 2013 | 28 | 0.540 |
Why?
|
Physicians | 3 | 2015 | 121 | 0.530 |
Why?
|
Tattooing | 2 | 2007 | 3 | 0.530 |
Why?
|
Adolescent | 11 | 2020 | 2324 | 0.530 |
Why?
|
Practice Patterns, Physicians' | 1 | 2017 | 122 | 0.520 |
Why?
|
Canada | 4 | 2018 | 51 | 0.510 |
Why?
|
Language | 6 | 2022 | 69 | 0.500 |
Why?
|
Biological Products | 1 | 2016 | 45 | 0.500 |
Why?
|
Linear Models | 6 | 2018 | 255 | 0.480 |
Why?
|
Arthritis, Rheumatoid | 4 | 2019 | 263 | 0.480 |
Why?
|
Immunoglobulin kappa-Chains | 1 | 2014 | 2 | 0.460 |
Why?
|
Immunoglobulin lambda-Chains | 1 | 2014 | 2 | 0.460 |
Why?
|
Interleukin-10 | 1 | 2014 | 20 | 0.460 |
Why?
|
United States | 7 | 2018 | 2185 | 0.460 |
Why?
|
Interleukin-6 | 1 | 2014 | 79 | 0.450 |
Why?
|
Autoantibodies | 8 | 2013 | 80 | 0.440 |
Why?
|
Posterior Leukoencephalopathy Syndrome | 1 | 2013 | 9 | 0.440 |
Why?
|
Patient Education as Topic | 1 | 2014 | 161 | 0.430 |
Why?
|
Treatment Outcome | 10 | 2018 | 3619 | 0.430 |
Why?
|
Teaching | 2 | 2019 | 61 | 0.420 |
Why?
|
Cultural Characteristics | 1 | 2013 | 21 | 0.420 |
Why?
|
Dermatology | 1 | 2012 | 6 | 0.410 |
Why?
|
Diagnostic Self Evaluation | 1 | 2012 | 14 | 0.410 |
Why?
|
Hospitals, County | 1 | 2012 | 3 | 0.410 |
Why?
|
Hospitals, University | 1 | 2012 | 28 | 0.400 |
Why?
|
Longitudinal Studies | 6 | 2020 | 1391 | 0.400 |
Why?
|
Caregivers | 1 | 2015 | 203 | 0.400 |
Why?
|
Adaptation, Psychological | 5 | 2016 | 183 | 0.400 |
Why?
|
Body Dysmorphic Disorders | 1 | 2011 | 2 | 0.390 |
Why?
|
Polymorphism, Single Nucleotide | 8 | 2017 | 285 | 0.390 |
Why?
|
Emotions | 3 | 2017 | 87 | 0.380 |
Why?
|
Immunoglobulin Light Chains | 1 | 2011 | 6 | 0.380 |
Why?
|
Aged | 10 | 2021 | 9339 | 0.350 |
Why?
|
Genetic Predisposition to Disease | 6 | 2018 | 382 | 0.350 |
Why?
|
Benchmarking | 1 | 2010 | 38 | 0.340 |
Why?
|
Demography | 1 | 2010 | 75 | 0.340 |
Why?
|
Income | 1 | 2010 | 78 | 0.330 |
Why?
|
Clinical Trials as Topic | 4 | 2016 | 236 | 0.330 |
Why?
|
Cognitive Dysfunction | 1 | 2019 | 1072 | 0.320 |
Why?
|
Predictive Value of Tests | 4 | 2017 | 494 | 0.310 |
Why?
|
Activities of Daily Living | 2 | 2012 | 612 | 0.310 |
Why?
|
Case-Control Studies | 6 | 2014 | 600 | 0.310 |
Why?
|
Stress, Psychological | 3 | 2020 | 243 | 0.300 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2016 | 329 | 0.300 |
Why?
|
Paracentesis | 1 | 2007 | 4 | 0.280 |
Why?
|
Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2007 | 2 | 0.280 |
Why?
|
Suction | 1 | 2007 | 40 | 0.280 |
Why?
|
Genital Diseases, Female | 1 | 2006 | 5 | 0.270 |
Why?
|
Reference Values | 3 | 2014 | 199 | 0.270 |
Why?
|
Chronic Disease | 2 | 2005 | 442 | 0.270 |
Why?
|
Hyperuricemia | 1 | 2006 | 4 | 0.260 |
Why?
|
Takayasu Arteritis | 1 | 2005 | 1 | 0.250 |
Why?
|
Uveitis | 1 | 2005 | 10 | 0.250 |
Why?
|
Chicago | 2 | 2018 | 941 | 0.250 |
Why?
|
Metabolic Syndrome | 1 | 2006 | 62 | 0.250 |
Why?
|
Leukoencephalopathy, Progressive Multifocal | 1 | 2007 | 113 | 0.250 |
Why?
|
Vasculitis | 1 | 2005 | 29 | 0.250 |
Why?
|
Pre-Eclampsia | 1 | 2004 | 7 | 0.240 |
Why?
|
Prognosis | 3 | 2014 | 824 | 0.240 |
Why?
|
Chlamydia trachomatis | 1 | 2004 | 6 | 0.230 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2005 | 192 | 0.230 |
Why?
|
Chlamydia Infections | 1 | 2004 | 7 | 0.230 |
Why?
|
Heart Diseases | 1 | 2005 | 68 | 0.230 |
Why?
|
Antibodies, Monoclonal | 1 | 2005 | 199 | 0.230 |
Why?
|
Pregnancy Complications | 1 | 2004 | 52 | 0.220 |
Why?
|
Depressive Disorder | 2 | 2018 | 184 | 0.220 |
Why?
|
Translations | 2 | 2013 | 12 | 0.220 |
Why?
|
Diagnosis, Differential | 3 | 2013 | 371 | 0.210 |
Why?
|
Comorbidity | 3 | 2013 | 502 | 0.210 |
Why?
|
Sex Factors | 2 | 2018 | 480 | 0.200 |
Why?
|
Patient Acceptance of Health Care | 1 | 2023 | 82 | 0.200 |
Why?
|
Cardiovascular Diseases | 1 | 2006 | 373 | 0.200 |
Why?
|
Vaccination | 1 | 2021 | 32 | 0.190 |
Why?
|
Immunocompromised Host | 1 | 2021 | 45 | 0.190 |
Why?
|
Prospective Studies | 3 | 2020 | 1810 | 0.180 |
Why?
|
Regression Analysis | 3 | 2020 | 267 | 0.180 |
Why?
|
Autoimmunity | 2 | 2010 | 13 | 0.170 |
Why?
|
Health Surveys | 2 | 2017 | 92 | 0.170 |
Why?
|
Cohort Studies | 6 | 2017 | 1948 | 0.170 |
Why?
|
Multivariate Analysis | 2 | 2018 | 334 | 0.170 |
Why?
|
Databases, Factual | 1 | 2021 | 358 | 0.170 |
Why?
|
Azacitidine | 1 | 2019 | 10 | 0.160 |
Why?
|
Age Factors | 3 | 2016 | 793 | 0.160 |
Why?
|
Asia | 1 | 2018 | 10 | 0.160 |
Why?
|
Enzyme Inhibitors | 1 | 2019 | 120 | 0.160 |
Why?
|
Europe | 1 | 2018 | 67 | 0.160 |
Why?
|
Appointments and Schedules | 1 | 2018 | 14 | 0.160 |
Why?
|
Morbidity | 1 | 2018 | 58 | 0.160 |
Why?
|
Mentors | 1 | 2019 | 43 | 0.160 |
Why?
|
Arthritis, Experimental | 1 | 2019 | 48 | 0.160 |
Why?
|
Sex Distribution | 1 | 2018 | 81 | 0.160 |
Why?
|
Patient Acuity | 1 | 2018 | 9 | 0.160 |
Why?
|
Workload | 1 | 2018 | 33 | 0.150 |
Why?
|
Faculty, Medical | 1 | 2019 | 39 | 0.150 |
Why?
|
Phenotype | 4 | 2012 | 308 | 0.150 |
Why?
|
Biomedical Research | 1 | 2019 | 66 | 0.150 |
Why?
|
Risk Assessment | 2 | 2014 | 676 | 0.150 |
Why?
|
DNA Methylation | 1 | 2019 | 163 | 0.150 |
Why?
|
Psychiatric Status Rating Scales | 1 | 2018 | 329 | 0.150 |
Why?
|
Pilot Projects | 2 | 2020 | 440 | 0.150 |
Why?
|
Interferon Type I | 2 | 2017 | 12 | 0.140 |
Why?
|
Genome-Wide Association Study | 4 | 2012 | 291 | 0.140 |
Why?
|
Blood Sedimentation | 1 | 2017 | 54 | 0.140 |
Why?
|
Philippines | 2 | 2017 | 4 | 0.140 |
Why?
|
Health Care Surveys | 1 | 2017 | 66 | 0.140 |
Why?
|
CD11b Antigen | 1 | 2017 | 15 | 0.140 |
Why?
|
Toll-Like Receptors | 1 | 2017 | 17 | 0.140 |
Why?
|
Retrospective Studies | 2 | 2018 | 3612 | 0.140 |
Why?
|
Illinois | 1 | 2017 | 247 | 0.130 |
Why?
|
Macrophages | 1 | 2017 | 107 | 0.130 |
Why?
|
Socioeconomic Factors | 3 | 2016 | 311 | 0.130 |
Why?
|
Health Status Disparities | 1 | 2017 | 75 | 0.130 |
Why?
|
France | 1 | 2016 | 18 | 0.130 |
Why?
|
Mental Health | 1 | 2017 | 123 | 0.130 |
Why?
|
Arthralgia | 2 | 2008 | 125 | 0.130 |
Why?
|
Sleep Initiation and Maintenance Disorders | 1 | 2017 | 108 | 0.130 |
Why?
|
Time Factors | 2 | 2017 | 1497 | 0.130 |
Why?
|
Hong Kong | 1 | 2015 | 2 | 0.120 |
Why?
|
Magnetic Resonance Imaging | 2 | 2013 | 1196 | 0.120 |
Why?
|
Interferon Regulatory Factor-7 | 2 | 2017 | 4 | 0.120 |
Why?
|
Software | 1 | 2015 | 67 | 0.120 |
Why?
|
Self Concept | 2 | 2012 | 43 | 0.120 |
Why?
|
Cosmetic Techniques | 1 | 2014 | 5 | 0.120 |
Why?
|
Professional-Patient Relations | 1 | 2015 | 28 | 0.120 |
Why?
|
Observational Studies as Topic | 1 | 2014 | 19 | 0.120 |
Why?
|
Double-Blind Method | 1 | 2016 | 424 | 0.120 |
Why?
|
Critical Pathways | 1 | 2014 | 21 | 0.120 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2015 | 349 | 0.120 |
Why?
|
Chi-Square Distribution | 1 | 2014 | 146 | 0.120 |
Why?
|
Focus Groups | 1 | 2014 | 93 | 0.120 |
Why?
|
Goals | 1 | 2014 | 44 | 0.110 |
Why?
|
Sleep | 1 | 2017 | 355 | 0.110 |
Why?
|
Genetic Variation | 2 | 2011 | 100 | 0.110 |
Why?
|
Combined Modality Therapy | 1 | 2014 | 306 | 0.110 |
Why?
|
Interferon Regulatory Factors | 1 | 2013 | 2 | 0.110 |
Why?
|
Turkey | 1 | 2013 | 6 | 0.110 |
Why?
|
Promoter Regions, Genetic | 2 | 2011 | 100 | 0.110 |
Why?
|
Latin America | 1 | 2013 | 5 | 0.110 |
Why?
|
Disease Management | 1 | 2013 | 114 | 0.100 |
Why?
|
Matched-Pair Analysis | 1 | 2012 | 30 | 0.100 |
Why?
|
Self-Assessment | 1 | 2012 | 30 | 0.100 |
Why?
|
Multiple Sclerosis | 1 | 2013 | 102 | 0.100 |
Why?
|
Quality Improvement | 1 | 2013 | 161 | 0.100 |
Why?
|
Feedback | 1 | 2012 | 33 | 0.100 |
Why?
|
Osteopontin | 1 | 2011 | 5 | 0.100 |
Why?
|
Ubiquitin-Conjugating Enzymes | 1 | 2011 | 5 | 0.100 |
Why?
|
Gene Expression Profiling | 1 | 2012 | 140 | 0.100 |
Why?
|
Sensitivity and Specificity | 1 | 2013 | 520 | 0.100 |
Why?
|
DEAD-box RNA Helicases | 1 | 2011 | 5 | 0.090 |
Why?
|
Complementary Therapies | 1 | 2011 | 8 | 0.090 |
Why?
|
DNA | 4 | 2013 | 104 | 0.090 |
Why?
|
Genetic Association Studies | 1 | 2011 | 86 | 0.090 |
Why?
|
Aged, 80 and over | 2 | 2019 | 4904 | 0.090 |
Why?
|
Alleles | 4 | 2011 | 213 | 0.090 |
Why?
|
Class III Phosphatidylinositol 3-Kinases | 1 | 2010 | 1 | 0.090 |
Why?
|
Models, Genetic | 1 | 2010 | 35 | 0.090 |
Why?
|
Epitopes | 1 | 2010 | 48 | 0.090 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2010 | 44 | 0.090 |
Why?
|
Disease Models, Animal | 2 | 2019 | 628 | 0.090 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2010 | 54 | 0.090 |
Why?
|
United Kingdom | 1 | 2010 | 54 | 0.080 |
Why?
|
Nuclear Proteins | 1 | 2010 | 86 | 0.080 |
Why?
|
Social Environment | 1 | 2010 | 84 | 0.080 |
Why?
|
Self-Examination | 1 | 2009 | 3 | 0.080 |
Why?
|
Follow-Up Studies | 1 | 2014 | 1868 | 0.080 |
Why?
|
California | 3 | 2017 | 32 | 0.080 |
Why?
|
Animals | 3 | 2019 | 3798 | 0.080 |
Why?
|
Cytokines | 1 | 2010 | 233 | 0.080 |
Why?
|
Educational Status | 1 | 2010 | 298 | 0.080 |
Why?
|
Analgesics, Non-Narcotic | 1 | 2008 | 17 | 0.070 |
Why?
|
Biomarkers | 1 | 2011 | 601 | 0.070 |
Why?
|
Prevalence | 2 | 2011 | 473 | 0.070 |
Why?
|
Therapeutic Irrigation | 1 | 2007 | 56 | 0.070 |
Why?
|
Fatal Outcome | 1 | 2007 | 58 | 0.070 |
Why?
|
Patient Satisfaction | 1 | 2010 | 329 | 0.070 |
Why?
|
Education, Medical, Undergraduate | 1 | 2007 | 33 | 0.070 |
Why?
|
Vulva | 1 | 2006 | 2 | 0.070 |
Why?
|
Data Collection | 1 | 2007 | 98 | 0.070 |
Why?
|
Injections, Intra-Articular | 1 | 2007 | 91 | 0.070 |
Why?
|
Joints | 1 | 2007 | 69 | 0.070 |
Why?
|
Skin Diseases | 1 | 2006 | 26 | 0.070 |
Why?
|
Cognition | 1 | 2014 | 1371 | 0.060 |
Why?
|
Disability Evaluation | 2 | 2020 | 293 | 0.060 |
Why?
|
Hepatitis B | 1 | 2005 | 12 | 0.060 |
Why?
|
Infliximab | 1 | 2005 | 17 | 0.060 |
Why?
|
Probability | 1 | 2005 | 91 | 0.060 |
Why?
|
Genotype | 3 | 2011 | 352 | 0.060 |
Why?
|
Autoimmune Diseases | 2 | 2019 | 47 | 0.060 |
Why?
|
Pregnancy Outcome | 1 | 2004 | 18 | 0.060 |
Why?
|
Sulfasalazine | 1 | 2004 | 3 | 0.060 |
Why?
|
Lactones | 1 | 2004 | 9 | 0.060 |
Why?
|
Sulfones | 1 | 2004 | 20 | 0.060 |
Why?
|
Doxycycline | 1 | 2004 | 16 | 0.060 |
Why?
|
Methotrexate | 1 | 2004 | 36 | 0.060 |
Why?
|
Myocardial Infarction | 1 | 2005 | 141 | 0.060 |
Why?
|
Drug Therapy, Combination | 1 | 2004 | 184 | 0.060 |
Why?
|
Synovial Fluid | 1 | 2004 | 95 | 0.060 |
Why?
|
Mice | 2 | 2019 | 1467 | 0.050 |
Why?
|
Internship and Residency | 1 | 2007 | 217 | 0.050 |
Why?
|
Osteoarthritis, Knee | 1 | 2008 | 363 | 0.050 |
Why?
|
Pregnancy | 1 | 2004 | 340 | 0.050 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2004 | 111 | 0.050 |
Why?
|
Prostaglandins A | 1 | 2022 | 1 | 0.050 |
Why?
|
Republic of Korea | 1 | 2022 | 6 | 0.050 |
Why?
|
Hypertension | 1 | 2004 | 226 | 0.050 |
Why?
|
Ribonucleoproteins | 2 | 2011 | 3 | 0.050 |
Why?
|
Cell Line | 2 | 2012 | 279 | 0.050 |
Why?
|
Anti-Bacterial Agents | 1 | 2004 | 376 | 0.050 |
Why?
|
Egypt | 1 | 2020 | 2 | 0.040 |
Why?
|
Polymorphism, Genetic | 2 | 2011 | 59 | 0.040 |
Why?
|
Chromatin Immunoprecipitation | 1 | 2019 | 22 | 0.040 |
Why?
|
Gene Silencing | 1 | 2019 | 26 | 0.040 |
Why?
|
Anxiety | 1 | 2020 | 161 | 0.040 |
Why?
|
Flow Cytometry | 1 | 2019 | 116 | 0.040 |
Why?
|
B-Lymphocytes | 1 | 2019 | 56 | 0.040 |
Why?
|
Malaria | 1 | 2018 | 4 | 0.040 |
Why?
|
Immunoglobulin M | 1 | 2018 | 16 | 0.040 |
Why?
|
Complement C1q | 1 | 2018 | 7 | 0.040 |
Why?
|
Glucocorticoids | 1 | 2018 | 70 | 0.040 |
Why?
|
Immunoglobulin G | 1 | 2018 | 94 | 0.040 |
Why?
|
Georgia | 1 | 2017 | 11 | 0.040 |
Why?
|
Southeastern United States | 1 | 2017 | 14 | 0.040 |
Why?
|
Mice, Inbred MRL lpr | 1 | 2017 | 2 | 0.040 |
Why?
|
Interferon Regulatory Factor-3 | 1 | 2017 | 2 | 0.040 |
Why?
|
Forkhead Box Protein O3 | 1 | 2017 | 5 | 0.040 |
Why?
|
Japan | 1 | 2016 | 7 | 0.030 |
Why?
|
Australia | 1 | 2016 | 43 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2017 | 51 | 0.030 |
Why?
|
Social Class | 1 | 2017 | 68 | 0.030 |
Why?
|
Registries | 1 | 2017 | 191 | 0.030 |
Why?
|
Child | 1 | 2020 | 1423 | 0.030 |
Why?
|
Disabled Persons | 1 | 2016 | 125 | 0.030 |
Why?
|
Risk Factors | 2 | 2011 | 2421 | 0.030 |
Why?
|
3' Untranslated Regions | 1 | 2011 | 5 | 0.020 |
Why?
|
Anemia, Hemolytic | 1 | 2011 | 4 | 0.020 |
Why?
|
Autoantigens | 1 | 2011 | 25 | 0.020 |
Why?
|
Thrombocytopenia | 1 | 2011 | 22 | 0.020 |
Why?
|
Interferon-Induced Helicase, IFIH1 | 1 | 2011 | 1 | 0.020 |
Why?
|
Mexican Americans | 1 | 2011 | 30 | 0.020 |
Why?
|
Receptors, Lysophosphatidic Acid | 1 | 2010 | 1 | 0.020 |
Why?
|
Databases, Genetic | 1 | 2010 | 9 | 0.020 |
Why?
|
Principal Component Analysis | 1 | 2010 | 26 | 0.020 |
Why?
|
Antibody Specificity | 1 | 2010 | 35 | 0.020 |
Why?
|
Aminopeptidases | 1 | 2010 | 7 | 0.020 |
Why?
|
Tumor Necrosis Factor alpha-Induced Protein 3 | 1 | 2010 | 1 | 0.020 |
Why?
|
Protein Structure, Quaternary | 1 | 2010 | 5 | 0.020 |
Why?
|
Immunoprecipitation | 1 | 2010 | 24 | 0.020 |
Why?
|
Immunoblotting | 1 | 2010 | 57 | 0.020 |
Why?
|
Genetic Loci | 1 | 2010 | 54 | 0.020 |
Why?
|
Interferon-gamma | 1 | 2010 | 82 | 0.020 |
Why?
|
Transfection | 1 | 2010 | 121 | 0.020 |
Why?
|
Gene Frequency | 1 | 2010 | 60 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 2010 | 117 | 0.020 |
Why?
|
Signal Transduction | 1 | 2011 | 448 | 0.020 |
Why?
|
Gene Expression Regulation | 1 | 2010 | 279 | 0.020 |
Why?
|
DNA-Binding Proteins | 1 | 2010 | 275 | 0.020 |
Why?
|
Algorithms | 1 | 2010 | 378 | 0.020 |
Why?
|
Knee Joint | 1 | 2008 | 754 | 0.010 |
Why?
|